Bristol Insiders

<div class='circular--portrait' style='background:#689CFD;color: #ffffff;font-size:4em;padding-top: 25px;;'>BM</div>
BMY -- USA Stock  

Report: 6th of August 2020  

Bristol Myers employes about 30 K people. The company is managed by 45 executives with total tenure of roughly 159 years, averaging almost 3.0 years of service per executive having 666.67 employees per reported executive. Break down of Bristol Myers management performance can provide insight into the company performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Bristol Myers Squibb future performance. Continue to Trending Equities.

Search Insiders

 
Refresh
  Ann Powell  President
Chief Human Resource Officer, Senior Vice President
  Adam Dubow  President
Senior Vice President Chief Compliance Officer and Ethics Officer
  Charles Bancroft  President
Chief Financial Officer, Executive Vice President - Global Business Operations

  Bristol Myers Return on Sales

Bristol Myers Management Team Effectiveness

Bristol Myers Squibb has Return on Asset of 5.82 % which means that on every $100 spent on asset it made $5.82 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 3.0 %, implying that it generated $3.0 on every 100 dollars invested. Bristol Myers management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. Return on Investment is likely to grow to 15.40 in 2020. Return on Average Assets is likely to grow to 0.07 in 2020Bristol Myers Total Assets are fairly stable at the moment as compared to the past year. Bristol Myers reported Total Assets of 129.94 Billion in 2019. Assets Non Current is likely to grow to about 108.5 B in 2020, whereas Current Assets are likely to drop slightly above 24.5 B in 2020. Bristol Myers Total Liabilities is fairly stable at the moment as compared to the past year. Bristol Myers reported Total Liabilities of 78.25 Billion in 2019. Liabilities Non Current is likely to grow to about 64.7 B in 2020, whereas Current Liabilities is likely to drop slightly above 15.2 B in 2020. Weighted Average Shares Diluted is likely to grow to about 1.9 B in 2020, whereas Weighted Average Shares is likely to drop slightly above 1.6 B in 2020.

  Bristol Myers Quarterly Total Assets

Bristol Myers Workforce Comparison

Bristol Myers Squibb is rated below average in number of employees category among related companies. The total workforce of Drug Manufacturers?General industry is currently estimated at about 612,793. Bristol Myers holds roughly 30,000 in number of employees claiming about 5% of equities under Drug Manufacturers?General industry.

Bristol Myers Profit Margins

The company has Net Profit Margin of 3.08 %, which may imply that it executes well on its competitive polices and has a good control over its expenditures and variable costs. This is considered to be average in the sector. In the same way, it shows Net Operating Margin of 37.35 % which entails that for every 100 dollars of revenue it generated 0.37 of operating income.

Bristol Myers Insider Trading

Bristol Myers Squibb Benchmark Summation

The output start index for this execution was eight with a total number of output elements of fifty-three. The Lowest value over a specified period line plots minimum value of Bristol Myers Squibb price series. View also all equity analysis or get more info about lowest value over a specified period math operators indicator.

Bristol Myers Stakeholders

Giovanni Caforio Chairman of the Board, Chief Executive Officer
Lamberto Andreotti Executive Chairman, Officer, Ex-Officio Member of Audit Committee, Ex-Officio Member of Committee on Directors and Corporate Governance and Ex-Officio Member of Compensation and Management Devel. Committee
Ann Powell Chief Human Resource Officer, Senior Vice President
Adam Dubow Senior Vice President Chief Compliance Officer and Ethics Officer
Charles Bancroft Chief Financial Officer, Executive Vice President - Global Business Operations
Louis Schmukler Executive Vice President, President - Global Product Development and Supply
Christopher Boerner Executive Vice President and Chief Commercial Officer
John Elicker Senior Vice President - Corporate Affairs and Investor Relations
David Elkins Executive Vice President and Chief Financial Officer Member of the Leadership Team
Anne Nielsen Senior Vice President Chief Compliance and Ethics Officer
Karen Santiago Senior Vice President, Corporate Controller
Emmanuel Blin Senior Vice President Chief Strategy Officer
Joseph Caldarella Senior Vice President Corporate Controller
Murdo Gordon Executive Vice President Chief Commercial Officer
Thomas Lynch Chief Scientific Officer, Executive Vice President
Samuel Moed Senior Vice President - Strategic Planning and Analysis
Ann Judge Chief Human Resource Officer, Senior Vice President Member of the Leadership Team
Sandra Leung Executive Vice President, General Counsel
Paul Autenried Chief Information Officer, Senior Vice President
Francis Cuss Executive Vice President Chief Scientific Officer
Paul Biondi Senior Vice President, Head of Strategy & Business Development
Kathryn Metcalfe Executive Vice President - Corporate Affairs Member of the Leadership Team
Togo West Independent Director
Karen Vousden Independent Director
Michael Bonney Independent Director
Alan Lacy Independent Director
Robert Bertolini Independent Director
Jose Baselga Independent Director
Gerald Storch Independent Director
Michael Grobstein Independent Director
Phyllis Yale Independent Director
Vicki Sato Lead Independent Director
Julia Haller Independent Director
Laurie Glimcher Independent Director
Lewis Campbell Independent Director
Dinesh Paliwal Independent Director
Theodore Samuels Independent Director
Matthew Emmens Independent Director
Peter Arduini Independent Director
Rupert Vessey Executive Vice President Research and Early Development Member of the Leadership Team
Nadim Ahmed Executive Vice President and President - Hematology
Joseph Eid Senior Vice President and Head of Global Medical Affairs Member of the Leadership Team
Samit Hirawat Executive Vice President Chief Medical Officer, Global Drug Development Member of the Leadership Team
Tim Power Vice President of Investor Relations
Elizabeth Mily Executive Vice President - Strategy & Business Development

About Bristol Myers Management Performance

The success or failure of an entity such as Bristol Myers Squibb often depends on how effective the management is. Bristol Myers management team is responsible for propelling the future growth in the right direction and for administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Bristol management before purchasing its stock. It's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Bristol management is utilizing all available resources in the best possible way? Also, how well is the company doing, relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity. Please read more on our stock advisor page.
Last ReportedProjected for 2020
Return on Investment 9.88  15.40 
Return on Average Assets 0.05  0.07 
Return on Average Equity 0.14  0.17 
Return on Invested Capital 0.14  0.18 
Return on Sales 0.19  0.20 
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. Bristol Myers operates under Drug ManufacturersGeneral classification in the United States and is traded on BATS Exchange. It employs 30000 people.

Bristol Myers Manpower Efficiency

Return on Bristol Myers Manpower

Revenue Per Employee774.9 K
Revenue Per Executive689.1 M
Net Income Per Employee106.8 K
Net Income Per Executive21.2 M
Working Capital Per Employee79.9 K
Working Capital Per Executive53.3 M

Per Employee

Bristol Myers Per Employee Growth Over Time

  Net Income Per Employee

  Revenue Per Employee

Continue to Trending Equities. Please also try Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page